20/20 GENESYSTEMS, INC.

Pioneering the Multi-Cancer Early Detection (MCED) blood testing market

Print
Claim My Business
Form C
View on Wefunder
Categories
Healthcare & Medical, Health & Fitness, Education, Repeat Founder
Min Investment
$500
Location
Gaithersburg, MD
Expected Close Date
April 30, 2025
Target Raise
$50.00K-$5.00M
No. Investors
62
Security Price
$5.34
Website
2020gene.com
Number of Employees
20
Cash
$4,089,461
Revenue
$1,424,304
Short Term Debt
$1,011,623
Cost of Goods
$1,315,166
Long Term Debt
$1,068,713
Net Income
$-6,391,309

Key Deal Facts

Most affordable, accessible, and accurate multi-cancer early detection blood test on the U.S. market
Ranked #134 on the 2023 Inc. 5000 list of the “Fastest Growing Companies in America” (#1 in MD)
Partnering with major supermarket chain for in-pharmacy testing beginning in 1H 2024
Early entrant into what is predicted to be a $50B market for multi-cancer early detection testing
Multiple issued or allowed patents in the U.S. and East Asia (available in Downloads section)
Groundbreaking partnership with a leading cancer center + big Asian funding in 1H 2024
Sales volume from our cancer testing more than doubled between 2022 and 2023
Fast Company “World Changing Ideas” Honorable Mention in 2022

Management Team / Advisory Board Bios

Repeat Founder
Founder has started a previous company funded with $2M+, Jonathan Cohen CEOJohns Hopkins MS in Biotech + 25 yrs leading medical diagnostics: partnerships, marketing, IP, & finance. Secured $25M+ in funding & championed pro-biotech legislation. Early pioneer & inventor in multi-cancer early detection blood testing., Michael Lebowitz Ph.D., Chief Scientific OfficerJohns Hopkins Ph.D. (Biochem, Cell & Mol Bio) with 30+ yrs life sciences R&D in cancer Dx & Tx. Adjunct Prof. (Biotech) at Johns Hopkins & U. of MD Baltimore County., Jiming Zhou Ph.D., Chief Operation Officer 20+ yrs academia & industry. Led $330M pharma project. Managed Covid testing for 20/20: 400,000+ tests, peak 3,000+ tests/day., John Compton Ph.D., Board Chair20/20 Chair & BioDx co-founder (sold to Opko). Led BioReference as VP (2007-2013). MIT BS (Bio/Physics), UC Berkeley Ph.D. (Biophysics)., Michael A. RossM.D., Board Member20/20 Director (2016-present). Grew Euclid Systems revenue 5x in 5 years (CEO 2015-2020). GWU Ob-Gyn clinical professor (since 1979). Boards experience in biotech & medical devices. BS (Chem/Bio) & MD., Anne ShiflettActing CFO30+ yrs mgmt, finance & accounting (19 yrs life sciences). Secured $200M+ funding (strategic, PE, VC, etc.). Led company from turnaround to $1.2B sale.
Amount Raised : $109,519
Reveal the Score by Voting
＿
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
ⓘ
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
ⓘ
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
ⓘ
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
ⓘ
The value of the company compared to similar companies raising money from investors.
Valuation

Research Reports

No reports have been submitted

Become a Reporter
Read Our Research Disclaimer

0 Comments

Post Comment